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Abstract Natural or synthetic materials may be used to
aid tissue repair of fracture or pathologies where there has
been a loss of bone mass. Polymeric materials have been
widely studied, aiming at their use in orthopaedics and
aesthetic plastic surgery. Polymeric biodegradable blends
formed from two or more kinds of polymers could present
faster degradation rate than homopolymers. The purpose of
this work was to compare the biological response of two
biomaterials: poly(L-lactic acid)PLLA and poly(L-lactic
acid)PLLA/poly(ethylene oxide)PEO blend. Forty four-
week-old rats were divided into two groups of 20 animals,
of which one group received PLLA and the other PLLA/
PEO implants. In each of the animals, one of the bioma-
terials was implanted in the proximal epiphysis of the right
tibia. Each group was divided into subgroups of 5 animals,
and sacrificed 2, 4, 8 and 16 weeks after surgery, respec-
tively. Samples were then processed for analysis by light
microscopy. Newly formed bone was found around both
PLLA and PLLA/PEO implants. PLLA/PEO blends had a
porous morphology after immersion in a buffer solution
and in vivo implantation. The proportion 50/50 PLLA/PEO
blend was adequate to promote this porous morphology,
which resulted in gradual bone tissue growth into the
implant.
1 Introduction
The skeleton is subject to several injuries, such as abnor-
mal development or osseous defects, where the bone loss
has been caused by tumor resection. Moreover, mechanical
traumas to the skeleton due to both automobile and occu-
pational accidents tend to affect young people at the most
productive period of their working life [1–3]. The material
of first choice in the treatment of bone defects is autoge-
nous bone graft. In spite of being an important resource for
bone reconstruction, its utilization is limited to small
quantities. In addition, complications such as donor-site
morbidity and postoperative reabsorption are likely to
occur [4]. In face of the challenge of finding a good sub-
stitute material for bone grafting, metals and ceramics have
been clinically used to reinforce or replace bone grafts.
Although the use of these alternate materials in maxillo-
facial and orthopaedical surgery had reported initially
positive results, it was later recommended with reservation,
given the possibility of bone reabsorption at the implant
site and fracture resulting from stress transfer. Moreover,
the need for subsequent surgery to remove the material
would lead to additional expenses and traumas [5].
Hydroxyapatite ceramics (HA) has shown to be biocom-
patible, nontoxic and osteointegrable. Nevertheless, in spite
of several applications in dentistry and cranial facial sur-
gery, this porous ceramics presents low mechanical
resistance, what restricts its usage [6]. Yet, researchers
have reported cytokine and protease expression and pro-
duction by fibroblasts, in response to particles released by
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HA implants in vitro. These proteins act on the develop-
ment of osteolysis, possibly leading to loss of material
when implanted [7]. In order to substituting both metals
and ceramics for more biointegrable and resistant materi-
als, several polymers have been studied and indicated for
medical applications. Poly(methylmethacrylate) PMMA
[8], as well as some biodegradable polymers, such as
poly(dioxanone) PDS [9] and poly(caprolactone) PCL [10],
are some of the polymers which have been researched.
Apart from the utilization of polymers in pure form,
researchers have prepared polymeric mixtures, denomi-
nated blends, with a view to controlling its mechanical
resistance and degradation speed. In order to facilitate
osseointegration with host tissue and even allow associa-
tion with osteoinductive drugs, different polymers might
be combined [11, 12]. The poly(L-lactic acid) PLLA/
poly(ethylene oxide)PEO blend has been investigated in
vitro tests [13] where PLLA/PEO membranes have been
submerged in a phosphate buffer solution pH 7.4 at 37C,
so as to simulate in vivo implant conditions. The objec-
tive of this work was to assess in vitro and in vivo
tissue response to poly(L-lactic acid) PLLA and 50/50
poly(L-lactic acid) PLLA/poly(ethylene oxide)PEO blend
when implanted in defects surgically produced in the tibia
of rats.
2 Materials and Methods
2.1 Production of blend discs
The blend was prepared by mixing PLLA (Medisorb;
MW = 300,000 g/mol) and PEO (Aldrich; MW =
200,000 g/mol) in a mini injector LMM-2017 Mini Max
Molder. Sticks of PLLA and 50/50 PLLA/PEO were pre-
pared through the melting of homopolymers at 190C,
using a 2.0 mm diameter and 9.3 cm high (internal
dimensions) mold, which remained at 120C during the
processing. The heating of the homopolymer mixture was
carried out for 1 min followed by 2 min of shearing and
mold injection. The mold was cooled at room temperature
for 20 min.
2.2 In vitro study
In vitro degradation tests were carried out using 50/50
PLLA/PEO blends. Samples were immersed in a buffer
solution (KH2PO4–NaOH; pH = 7.4) at 37C, which was
changed every day. Tests were performed during a 2-week
period. These conditions have often been referred to in
literature as degradation tests [14]. Blends were immersed
for different periods (7 or 14 days). After each period,
samples were dried at 50C until they reached a constant
mass. The mass loss percentage was calculated by com-
paring mass values of the samples before and after
submitting them to degradation tests. Samples are denoted
here as a function of the degradation time. PLLA/PEO
t = 0 was used for blends that were not immersed in the
buffer solution, whereas PLLA/PEO t = 7 or t = 14 days
were used for blends that went through the degradation
process. Samples were fractured after immersion into
liquid nitrogen. Surface fracture was covered with gold by
sputtering and observed in a JEOL JXA 840 scanning
electron microscope.
2.3 In vivo study
A total of 44-week-old male albino Wistar rats (Rattus
norvegicus) were used. The animals were anesthetized with
a solution of 1:1 Chlorhydrate of Xylazine (Virbaxyl
2%) + Ketamine (Francotar) administered intramuscu-
larly at the dose of 1.5 ml/kg body weight. A longitudinal
incision was made through the skin on the medial surface
of the right posterior limb below the knee. The muscular
tissue and the periosteum were removed to expose the
cortical bone of the medial face of the proximal epiphysis
of the tibia. After that, a bone defect was produced with a
2 mm diameter drill attached to a low-speed dental engine.
During the procedure, the wound was flushed with isotonic
saline to reduce heat generation and limit the temperature
to which the bone was exposed. The bone defect was filled
with a 2 mm long and 2 mm in diameter cylinder-shaped
implant. The animals were divided into two groups, 20
animals received the implant of poly(L-lactic acid) PLLA/
poly(ethylene oxide)PEO blend and the remaining 20 ani-
mals received the poly(L-lactic acid) PLLA implant. After
the 2, 4, 8 and 16-week post-surgical periods the animals
were sacrificed with a lethal dose of the anesthetic and the
right tibia were dissected. The segment of the bone con-
tained the implant was fixed in a 10% formaline buffered
solution 0.1 M pH 7.3 for 72 h. Right after that, the sam-
ples were immersed in EDTA solution for decalcification.
The samples were paraffin-embedded and transversal sec-
tions (7 lm) were obtained and stained with Hematoxylin
and Eosin (HE).
The experimental protocol used in this work is in
agreement with both the standards of The American
Society for Testing and Materials (ASTM F-981-93) and
the Ethical Principles for Animal Experimentation adopted
by the Brazilian Animal Experimentation Board (COBEA).
It was also approved by the Internal Ethics in Animal
Experimentation Commission (CEEA) from the Biology
Institute of The State University of Campinas IB-UNI-
CAMP under protocol number 097-02.
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3 Morphometry and statistical analysis
The volume of newly formed bone closed to implants was
obtained using a 100-point quadrilateral grid system cou-
pled to the ocular (109) of a Carl Zeiss light microscope.
Five areas of the implantation site of each animal were
used for quantification. The volume (%) of bone was cal-
culated using the formula Vv = Pp/Pt, where Vv is the
volume, Pp is the number of points on the newly formed
bone, and Pt the total number of the system points (100),
according to the Delesse Principle [15].
Statistical analysis was conducted for two variables:
material implanted (PLLA and PLLA/PEO) and experi-
mental periods. Nonparametric variance was carried out,
coupled with the respective multiple-comparison tests [16].
Analyses of statistic test were made using significance
level of 0.05.
4 Results
4.1 In vitro study
The mass loss percentage for PLLA/PEO blend occurred
during the period of 14 days of in vitro degradation. The
highest mass loss percentage occurred during the first week
of in vitro degradation (47.0% in t = 7 days and 46.0% in
t = 14 days). This process is related to water diffusion in
the blend followed by dissolution of the PEO fraction.
Since the PLLA fraction presents a low degradation rate,
mass loss practically did not change during the period from
7 to 14 days of degradation. The Fig. 1 shows the surface
fracture of PLLA/PEO blend observed by scanning electron
microscopy as a function of the degradation time. For
samples, which were not immersed into the buffer solution
(t = 0), the occurrence of phase separation was not clear.
However, after a period in a buffer, all the channels could be
observed. The morphology of the blends at the end of the
first week (t = 7 days) was similar to that shown in blends
at the end of the second week (t = 14 days). For 50/50
PLLA/PEO blends, an intermediate situation was found,
where the dense structure became cracked and surrounded
by channels with pores in them.
4.2 Microscopic observations
4.2.1 PLLA implants
An immature bone layer was formed around the PLLA
implant 2 weeks after the implantation (Fig. 2a). The
defect in the cortical layer of the bone was filled with blood
vessels, connective tissue and inflammatory cells. After
4 weeks, the defect was partially filled by bone tissue.
Some areas of the bone layer formed around the implant
presented mature aspect, in which the matrix showed small
lacunae. After 8 weeks, the defect in the cortical layer was
filled with secondary bone and connective tissue cells. The
bone layer around the implant was thicker and uniform
than in other periods. A thin layer of fibroblast-like cells
was formed on the surface of the implant (Fig. 2b). After
16 weeks, the defect of the cortical layer was filled with
bone tissue. The newly formed bone layer around the
implant presented mature aspect. In two animals, there
were some little spaces formed on the surface of the
implants, which were filled with bone tissue.
4.2.2 PLLA/PEO blend implants
Bone formation occurred around the implant two weeks
after the implantation of the blend. The defect was occupied
mainly by connective tissue with indifferentiated cells,
which had also invaded spaces formed on surface of the
implant in the blend (Fig. 2c). Four weeks after implanta-
tion, the layer of newly formed bone surrounding the
implant was thicker. Bone formation and connective tissue
were observed in the defect of the cortical region. After
8 weeks the layer of newly formed bone surrounding the
implant was evidentially thicker than in the previous peri-
ods. Several spaces were present in the implants, which
were filled by bone tissue (Fig. 2d). With 16 weeks, the
defect of the cortical layer of the tibia was completely filled
by mature bone tissue. In two animals, greater amount of
Fig. 1 Scan photomicroscopy
of 50/50 PLLA/PEO blend. (a)
Before immersion in buffer
solution (t = 0), (b) after
immersion in buffer solution
(t = 14). 5009
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spaces was filled by bone than previous periods. Other
microscopic aspects were similar to the animals of 8 weeks.
5 Quantitative analysis
According to Fig. 3 and Table 1, the animals with PLLA/
PEO blend showed no significant difference as to the
volume of newly formed bone between 2 and 4 weeks of
implantation. However, the values obtained for bone vol-
ume in animals with PLLA/PEO after 8 weeks were
significantly bigger and remained constant until the six-
teenth week. After 8 and 16 weeks the volume of newly
formed closed to PLLA and PLLA/PEO bone increased.
Fig. 2 (a) PLLA 2 weeks after
surgery: bone tissue (arrows)
around the implant (I); Cortical
(cc). 239 (b) PLLA 8 weeks
after surgery: bone tissue (to)
around the implant; fibroblast-
like cells (arrows) close to
implant (I); bone marrow (mo).
1139 (c) PLLA/PEO 2 weeks
after implant showing tissue
grown into the blend; bone
(arrows) formed around the
implant; cortical (cc); bone
marrow (mo). 239 (d) PLLA/
PEO implant 8 weeks after
surgery: cell proliferation
(arrows) and bone tissue (to)
grown into implant; cortical








2 weeks 4 weeks 8 weeks 16 weeks
PLLA/PEO
PLLA
Fig. 3 Volume percent of newly formed bone close to PLLA and
PLLA/PEO implant
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However, the volume of bone formed around the PLLA/
PEO blend implants was significantly greater.
6 Discussion
Bone tissue was formed in all implantation sites of both
PLLA and PLLA/PEO groups. In PLLA implants, bone
tissue surrounded the whole implant surface, whereas in the
PLLA/PEO group, besides the newly formed bone tissue
around the implant, bone tissue was also found in grooves
formed along the surface of the implant. According to Refs.
[17] and [18], this bone layer that surrounded the implants
is a tissue response to surgical implantation procedure.
Osteogenic cells from the cortical layer, bone trabeculae
and bone marrow were stimulated. After 4 weeks, there
was a noticeable increase in the spaces formed inside
PLLA/PEO implants, which were gradually filled by bone
tissue. This result suggests that the action of the extra
cellular fluid and the tissue response at the implantation site
induced the degradation of the bend, leading a continuous
increase of the spaces formed into the implant.
The PLLA/PEO implant degradation is due the PEO
fraction of the blend. PEO is a polymer that quickly dis-
solves when in contact with tissular liquids. This
assumption may be confirmed in vitro and by the formation
of spaces inside the blend from the fourth week of
implantation, which confer porosity to implant. Because
PEO degradation provides adequate porosity for tissue
ingrown to implant, the proportions between the polymers
utilized in the preparation of the blend should be consid-
ered. The proportion 50/50 PLLA/PEO blend, utilized in
this work, was found to be adequate for allowing bone tissue
ingrown to implant. On the other hand, PLLA pure implants
did not dissolve in the same way to allow bone tissue
ingrown to implant. PLLA is a polymer that dissolves
slowly, what, however, does not reduce its biocompatibility
[18, 19]. Meikle et al. [20], studying 50/50 poly(DL-lactic
acid)/poly(glycolic acid) associated with bone growing
factors (BMP) in rabbit cranial defect repair, concluded that
this blend allowed bone repair and the degradation of the
polymer contributed for the release of BMP.
Regarding the volume of newly formed bone closed to
implants, between 2 and 4 weeks following implantation,
the amount it obtained for both PLLA and PLLA/PEO
implants were equivalent. However, from the eighth week
on, there was a significant increase of bone volume in the
PLLA/PEO blend compared that PLLA implants, what was
observed until the end of the experiment. This bone volume
difference found between the two types of implants from
eighth week is due the time of degradation of them, which
was less for the PLLA/PEO blend. Thus, the PLLA/PEO
blend became gradually more porous and allowed bone
tissue ingrown closed to implants.
The results obtained in this work showed no evidence of
incompatibility for both PLLA and PLLA/PEO implants
after implantation. However, the PLLA/PEO blends pro-
moted better osseointegration with host tissue than PLLA.
In addition, PLLA/PEO blend might offer other alterna-
tives for bone reaper treatment, such its association with
antibiotic drugs to prevent bone infections [21–23], or even
its association to osteoinductive proteins, such as BMP—
Bone Morphogenetic Protein [24–26].
7 Conclusions
Based on our results, we conclude that the PLLA/PEO
blends had a porous morphology after immersion in a
buffer solution and in vivo implantation. The proportion
50/50 PLLA/PEO blend was adequate to promote this
porous morphology and consequent gradual bone tissue
growth into implant. Finally, neither PLLA nor PLLA/PEO
implants showed evidence of incompatibility.
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